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Background: The wide variability in prevalence of childhood
asthma across Asia Pacific is well documented, but less is known
about its trends in mortality and hospitalization.
Objectives: To examine pediatric asthma mortality and hospitaliza-
tion trends of selected countries across Asia Pacific, and also
patterns of asthma drug utilization.
Materials and Methods: Mortality and population data were
sourced from the World Health Organization’s mortality database.
Data on hospitalization were obtained by direct inquiry and from
government and scientific publications. Drug use for asthma was
expressed as a controller-to-reliever (C:R) ratio (ie, units of inhaled
corticosteroids/units of short-acting -agonists, sold in each coun-
try). Time-series regression analyses were used to examine temporal
patterns and study association between deaths, hospitalizations, and
drug use.
Results: Japan showed a decreasing trend in pediatric asthma
mortality whereas an increase was observed in Thailand. Hospital-
izations decreased in Australia and Singapore but increased in
Taiwan, Republic of China. C:R ratios increased significantly across
the countries.
Conclusions: Mixed trends in pediatric asthma mortality and hos-
pitalization rates were observed, which coincided with a uniform
increase in C:R ratios. This may reflect importance of other aspects
of asthma management besides pharmacotherapy.
Key Words: Asia Pacific, pediatric asthma, asthma mortality
trends, asthma hospitalization trends, asthma drug utilization
pattern, controllers, relievers, inhaled corticosteroids, short-acting
-agonists
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INTRODUCTION
The global prevalence of asthma has increased over thepast few decades and it has been estimated that asthma
currently affects 300 million people worldwide.1 In Asia
Pacific (East Asia, Southeast Asia, and Oceania), recent
ISAAC (International Study on Asthma and Allergies in
Childhood) surveys revealed varying trends in childhood
asthma across this economically and culturally diverse re-
gion.2,3 Studies in Hong Kong Special Administrative Region
(SAR), Japan, and Singapore, among others, have shown
declining trends in asthma mortality and hospitalization, and
these trends have also been examined in relation to changing
patterns of asthma drug use.4–7 However, most studies did not
focus on the pediatric age group and less developed countries
in this region.
Inhaled corticosteroids (ICS) have been associated with
stabilized or decreasing asthma deaths and hospitalizations
observed in countries like Switzerland and the United States
since the 1990s.8–10 Further, ICS have been found to reduce
asthma hospitalization rates by as much as 80% and they
significantly reduce mortality rates with regular use.11 In
contrast, short-acting -agonists (SABA) can induce toler-
ance and increase airway hyperresponsiveness.12,13 Excess
use of SABA has also been found to increase the risk of
asthma death.14
However, despite the benefits of ICS in asthma man-
agement, uptake of the drug had been less than ideal in Asia
Pacific. A previous study by Lai et al found the use of ICS in
this region to be only 13.6% compared to 23% in Europe,
with many patients expressing concerns over side effects
related to its chronic use.15 Hence, the aim of this paper is to
examine recent trends in pediatric asthma mortality and
hospitalization rates and asthma drug utilization patterns
across the Asia Pacific.
MATERIALS AND METHODS
Data Sources
Data were sourced from members of the Asia Pacific
Association of Pediatric Allergy, Respirology and Immunol-
ogy (APAPARI) Australia, China, Hong Kong SAR,
From the 1Department of Pediatrics, National University of Singapore,
Singapore; and 2Epidemiology & Disease Control Division, Ministry of
Health, Singapore.
Presented at the 7th Asia Pacific Association of Pediatric Allergy, Respirology
and Immunology (APAPARI) Meeting, October 3–5, 2008, Singapore.
Corresponding author: Bee Wah Lee, Department of Pediatrics, National Uni-
versity of Singapore, 5 Lower Kent Ridge Road, Singapore 119074. Tel:
65 6772 4112. Fax: 65 6779 7486. E-mail: paeleebw@nus.edu.sg.
Copyright © 2009 by World Allergy Organization
WAO Journal ● May 2009 77
Indonesia, Japan, Korea, Malaysia, New Zealand, Philip-
pines, Singapore, Taiwan [(Republic of China, ROC) and
Thailand, which although not comprehensive does represent
the diversity of this region in terms of culture and economic
development. To examine temporal trends from a common
time period, the earliest year for which respective data were
available for most countries was used as the starting point of
data collection and analysis.
Yearly mortality and population data of the selected
countries (including special territories and regions) from
1990 to latest data available (range, 1996–2006) were
sourced from the World Health Organization’s (WHO) mor-
tality database.16 Annual data on hospitalization from 1994 to
latest data available (range, 2002–2006) were obtained by
direct inquiry and from government and scientific publica-
tions.17,18 Data on asthma drug use from 1997 to 2007 were
provided by IMS Health Incorporated, a pharmaceutical mar-
ket intelligence company.
Cause-specific mortality data from the WHO mortality
database were reported according to the International Classi-
fication of Diseases (ICD). When member countries used
ICD-9 (the ninth revision), deaths due to asthma were ex-
tracted using Basic Tabulation List code B323, which in-
cluded deaths due to bronchitis and emphysema. Extracting
absolute asthma deaths was possible only in less than 5
countries studied that adopted the ICD-10 coding system, in
which deaths due to asthma were separately classified. Be-
cause Anderson et al19 found that in 5- to 14-year-olds asthma
constitutes 89.8% of deaths under the B323 category and a
temporal trend in deaths coded B323 reflected mainly that of
asthma, asthma mortality rates of the same age group in each
country were calculated using the total number of asthma
deaths, by proxy of deaths coded ICD-9 B323 or its equiva-
lent in ICD-10 (J40-43, J45-46), divided by the total popu-
lation to maintain consistency. For countries where popula-
tion data were missing from some years, a cubic regression
line was fitted to interpolate the missing data.
Annual hospitalization rates of 0- to 14-year-olds in
each selected country were examined. The 0- to 4-year olds
were included to improve consistency of data between coun-
tries as data were stratified from 0 to 18 years in Taiwan,
ROC. Drug utilization patterns in terms of the ratio of
corticosteroids to bronchodilators (C:B) have been demon-
strated to be a reliable indicator of quality of asthma prescrib-
ing in primary care, and it is also associated with asthma
outcomes.20,21 In this study, drug utilization patterns were
examined through a modified C:B, where we defined control-
ler-to-reliever ratio (C:R) as the ratio of the total number of
units of controllers (ICS and its combinations) to the total
number of units of relievers (SABA) sold in each selected
country. C:R was chosen in consideration of the Global
Initiative for Asthma program guidelines in asthma prescrib-
ing, which recommend as needed SABA with the option of
adding a controller to achieve asthma control.22 In addition,
expressing drug utilization patterns as C:R circumvents the
problem of missing population data from the WHO mortality
database for some countries.
Statistical Analyses
Statistical software SPSS 16.0 for Windows23 was used
for data analyses. Poisson regression analysis was used to
analyze temporal trends in yearly death counts of individual
countries. An offset of log-transformed population variables
was used to account for population growth. In addition, to
account for the step change associated with the change in ICD
coding in some countries during the study period, a dummy
variable was introduced in the analyses of WHO mortality
data from countries that adapted from ICD-9 to ICD-10.
Linear regression analysis was used to analyze trends in
hospitalization rates and C:R (both with log-transformation).
Three countries—Australia, Hong Kong SAR, and Singa-
pore—that had the most comprehensive annual data were
chosen for further analysis of association between drug uti-
lization patterns and mortality or hospitalization rates.
The equations for the respective models of Poisson and
linear regressions are shown together with Tables 1–4 (foot-
notes). The regression coefficients, 1 and 2, each refer to
the slope when the dependent variable— death counts, hos-
pitalization rates, or C:R—is regressed on the independent
variable, time in years or log(C:R). These regression coeffi-
cients (1 and 2) would be interpreted as the average annual
percentage change of the dependent variable in relation to the
independent variable.
Data on prevalence of asthma in children were gathered
from published ISAAC studies to look at trends in prevalence
and to compare those with trends in asthma mortality and
hospitalization rates. Further analysis between trends in prev-
alence of current wheeze (any wheeze in the past 12 months)
and trends in mortality and hospitalization was done using
Spearman’s rank correlation, comparing the average change
per year in prevalence and the average change per year in
mortality or hospitalization rates over the same period.
There were some limitations in the availability of data.
Few countries in this study had reported both ISAAC Phase
I and Phase III prevalence data. Data on mortality and
prevalence of current wheeze were available from 7 countries
(Australia, Hong Kong SAR, Japan, Korea, New Zealand,
Singapore, and Thailand) for 6- to 7-year-olds, and from 6
countries (Hong Kong SAR, Japan, Korea, New Zealand,
Singapore, and Thailand) for 13- to 14-year-olds. There were
only 4 countries (Australia, Hong Kong SAR, Singapore, and
Taiwan, ROC) with relevant hospitalization and prevalence
data for 6- to 7-year-olds, and only 3 countries (Hong Kong
SAR, Singapore, and Taiwan, ROC) had comparable data for
13- to 14-year-olds.
RESULTS
Time-series plots of trends in crude asthma mortality,
hospitalization rates, and pattern of drug utilization for each
selected country are shown in Figures 1–3. For Figure 1,
3-year moving averages were plotted to smooth out fluctua-
tions in mortality rates, and log-scale was also chosen to
show the trends more clearly. Where no deaths were recorded
in any year, 0.5 deaths was replaced to obtain valid estimates
with log-transformation. A summary of data availability is
presented in Table 1. Results from regression analyses of
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trends and correlation analyses are presented in Tables 2–4.
Mixed trends in asthma mortality and hospitalizations were
observed across Asia Pacific (Figs. 1, 2). However, 6 of 9
selected countries with data available showed a decrease in
mortality, albeit not statistically significant except for Japan
(1  0.163, P  0.001). A small but significant increase
was noted for Thailand (1  0.093, P  0.006) (Table 2).
Similar results were found for hospitalizations, with 4
of 5 countries registering a decrease, with significant de-
creases in both Singapore (1  0.090, P  0.001) and
Australia (1  0.067, P  0.001), whereas a significant
increase was observed in Taiwan, ROC (1  0.065, P 
0.001) (Table 2).
The general decline in asthma mortality and hospital-
izations across Asia Pacific (Figs. 1, 2) coincided with sig-
nificant increases in C:R ratios across the region (Fig. 3).
Despite China having the highest increase in C:R (1 
0.190, P  0.001), an increase in mortality was observed,
although not significant. In contrast, Japan, which had a
comparable increase in C:R (1 0.188, P 0.001), showed
the highest significant decrease in mortality rates (Table 2).
Negative associations were also observed for both asthma
mortality and hospitalizations with C:R in Australia, Hong
Kong SAR, and Singapore, but these were not statistically
significant (Table 3).
No significant correlations existed between trends in
prevalence of current wheeze and trends in asthma mortality
or hospitalizations. Interestingly, a negative correlation (P 
0.072) was found between prevalence in 13- to 14-year-olds
and mortality (Table 4).
DISCUSSION
This was an exploratory study to provide an overview
of childhood asthma mortality and hospitalization, and the
pattern of asthma drug use across the Asia Pacific. It is
acknowledged that the data obtained may not be uniformly
accurate. Mortality data from WHO are subject to inherent
errors as they are dependent upon individual country’s report
of statistics. Completeness of death and population registra-
tion coverage and accuracy of asthma death certification
would likely differ between countries. Further, variations in
management practices, including severity threshold for hos-
pital admission, and patient behavior would affect the
FIGURE 2. Hospitalization rates of 0- to 14-year-olds from
1994 to last available data. * indicates point prevalence;
∧, 0- to 18-year-olds.
FIGURE 1. Mortality rates of 5- to 14-year-olds from 1990
to last data available.
FIGURE 3. Trends in C:R for total population from 1997 to
2007.
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comparison of hospitalization rates between countries. Nev-
ertheless, the trends and correlations presented in this study
would provide insight into the state of pediatric asthma across
this region and possibly serve as a springboard for future
studies in this area.
Most countries did not show statistically significant
trends in asthma mortality. Deaths from asthma are relatively
uncommon, especially in children. Therefore, mortality rates
are subject to greater random variations, which may lead to
less power in achieving statistical significance. Further, the
paucity of asthma hospitalization data in some populations
also contributed to difficulties in the identification and com-
parison of trends in this region.
However, it should be noted that the countries (Austra-
lia, Japan, and Singapore) with significant decreases in
asthma mortality and hospitalization rates are paradoxically
countries with higher asthma prevalence rates in the region.24
The higher rates of current wheeze in these countries have
been attributed to higher degrees of urbanization and west-
ernization.1,25 These countries are also more affluent, and it is
TABLE 2. Trends in Pediatric Asthma Mortality, Hospitalization, and C:R
Countries
Asthma Mortality* Asthma Hospitalization† C:R‡
1 P 1 P 1 P
Australia 0.076 0.054 0.067 0.001 0.074 0.001
China 0.028 0.312 NA NA 0.190 0.001
Hong Kong SAR 0.120 0.072 0.015 0.227 0.051 0.433
Indonesia NA NA NA NA 0.129 0.001
Japan 0.163 0.001 0.003 0.840 0.188 0.001
Korea 0.007 0.859 NA NA 0.127 0.001
Malaysia NA NA NA NA 0.087 0.001
New Zealand 0.092 0.397 NA NA 0.015 0.011
Philippines 0.005 0.475 NA NA 0.079 0.001
Singapore 0.069 0.098 0.090 0.001 0.054 0.001
Taiwan, ROC NA NA 0.065 0.001 0.125 0.001
Thailand 0.093 0.006 NA NA 0.106 0.001
*Poisson regression analysis: log(expected no. of age-specific deaths due to asthma)  0  log(age-specific population size)  1  year.
†Linear regression analysis: log(hospitalization rates)  0  1  year.
‡Linear regression analysis: log(C:R ratio)  0  1  year.
TABLE 1. Summary of Data Availability
Countries















Australia 1993 NA 2002 NA 1990–2003 1994–2003
China NA 1994 NA 2001 1990–1999 NA
Hong Kong SAR 1995 2001 2002 1990–2005 1994–2005
Indonesia 1996 2002 NA NA
Japan 1994 2002 1990–2006 1993–2002§ 1997–2007#
Korea 1995 2000 1990–2006 NA
Malaysia 1995 2001 NA NA
New Zealand 1993 2001 1990–2004 NA
Philippines NA 1994 NA 2001 1992–1998 NA
Singapore 1994 2001 1990–2006 1994–2006
Taiwan, ROC 1995 2001 NA 1996–2002¶
Thailand 1995 2001 1990–2002 NA
*Data on asthma mortality in 5- to 14-year-olds.
†
Data on asthma hospitalization in 0- to 14-year-olds (except Taiwan).
‡Data on drug sales for total population.
§Cross-sectional data in 1 day; data reported every 3 years.
¶Data from 0- to 18-year-olds.
Data missing from 1993 and 2001.
#Data on drug sales in China from 1999.
Chua et al WAO Journal • May 2009
© 2009 World Allergy Organization80
plausible that the quality of and access to health care is better.
Further, the higher prevalence of asthma could have encour-
aged local health authorities or health care institutions to
place a greater emphasis on management of asthma. In
Australia, where asthma prevalence is one of the highest in
the world,24,25 organizations like the National Asthma Coun-
cil Australia26 and Asthma Foundations Australia27 have been
set up to improve the quality of life of asthma sufferers.
Similarly, the Singapore National Asthma Program (SNAP)
was implemented in 2001, with the goal to ease asthma
burden by encouraging the use of controllers and reducing the
reliance on relievers, among other initiatives.28
In contrast, the 2 countries—Thailand and Taiwan,
ROC—that experienced increases in asthma mortality and
hospitalization rates have relatively lower asthma prevalence
rates.24 However, the recent upward trend in asthma preva-
lence in these countries2,3 may at least in part explain the
observed rising trends in asthma mortality and hospitaliza-
tions, as suggested by the positive correlation coefficients
(P  0.05) (Table 4). These results are also consistent with
those reported by Anderson et al,19 who analyzed interna-
tional data from various ISAAC centers. Another plausible
factor is a lack of good management practices by general
practitioners, as asthma is mostly managed in the primary
care setting.18
Negative correlations, though not attaining statistical
significance, between trends in asthma mortality or hospital-
ization rates and C:R were found in 3 countries—Australia,
Hong Kong SAR, and Singapore. It should however be noted
that C:R obtained represented those of the entire population
and not just the pediatric age group. Stafford et al,29 who
looked at the US national data, reported similar results; an
increase in controller use coupled with a decrease in reliever
use corresponded with stabilization of asthma visits.
Although a uniform increase in C:R was observed in
the Asia Pacific countries studied, the characteristics of a
ratio should be considered. As long as the increase in con-
trollers surpasses that of relievers, or the decrease in relievers
outstrips that of controllers, both will result in an increase in
C:R. However, our data showed that sales of controllers have
been increasing in all countries studied, despite a mixed trend
in sales of relievers.
Of interest is a downward kink in both the hospitaliza-
tion rates and C:R from Hong Kong SAR, which coincided
with the outbreak of severe acute respiratory syndrome
(SARS) in 2003. There was a sharp decline in asthma hos-
pitalization rates following the SARS outbreak. This obser-
vation further suggests that hospital admissions for asthma in
developed countries may be affected by extraneous factors.
One of the reasons for the drop in asthma hospitalizations
could be due to changes in hospital policies that resulted in
the prohibition of nebulizer use. In its replacement, metered-
dose inhalers with spacers, which were also more readily
available in households, were used. This practice could also
explain the sharp decline in C:R. The total number of units of
relievers sold in 2004 (924,700 units) more than doubled that
in 2003 (409,400 units). Similar changes were not observed
in other countries affected by SARS. The low asthma hospi-
talization rates and C:R were sustained in the years after
SARS in Hong Kong SAR. Although difficult to verify, the
practice of health-seeking behaviors like frequent hand wash-
ing, adherence to doctors’ advice, regular exercise, and fre-
quent use of masks when having symptoms of influenza
post-SARS as described by Lau et al30 may have reduced
respiratory viral infections and, therefore, viral-triggered
wheezing. Hospitals in Hong Kong SAR also continued to
abide by the policy introduced during SARS, prohibiting use
of nebulizers, which possibly explains the sustained high
reliever sales.
On one hand, although the data suggest that the burden
of asthma in children in terms of hospitalization and mortality
appears to be declining, there is also concern that these
indicators seem to be increasing in some countries across
Asia Pacific. On the other hand, these observations coincided
with a uniform increase in C:R ratios across this region. Thus,
it is prudent to note that medication is only 1 aspect of asthma
management, reflected by the opposing mortality and hospi-
talization trends observed in different countries. A multi-
pronged approach, including proper counseling, social sup-
port, and access to quality medical care, is probably necessary
to reduce the mortality and hospitalizations in asthmatic
children.
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